Meta AnalysisID 7753
不同类型和剂量的他汀类药物使用与新发糖尿病风险：一项网状Meta分析
CRD42023470840
The aim of this network meta-analysis (NMA) is to compare and rank the risk of new-onset diabetes in use different doses of statins patients.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7753
- Evidence Id
- 16311
- Core Evidence Id
- 16311
- Source Meta Analysis Id
- 7751
- Herb2 Meta Analysis Id
- HBMA007751
- Crd Id
- CRD42023470840
- Title
- Different Types and Doses of Statins Use and The Risk of Developing New-onset Diabetes: A Network Meta-Analysis
- Review Question
- The aim of this network meta-analysis (NMA) is to compare and rank the risk of new-onset diabetes in use different doses of statins patients.
- Study Type Included
- Randomized controlled trials. Case reports and series', reviews, editorials, opinions, comments, book chapters, news paper items, systematic reviews, metanalyses, conference abstracts and conference presentations etc. will be excluded.
- Condition Being Studied
- Statins, the first-line drug for treating dyslipidemia, are currently amongst the most widely used drugs. However, several studies have linked statins to a higher risk of developing new‐onset diabetes, and potentially worsening glycemic control in patients with type 2 diabetes. To elucidate which type or dose of statin increased the risk of diabetes, we conducted this NMA to compare and rank the risk of new-onset diabetes with different types and doses of statins.
- Participant
- All patients with statin use irrespective of the indication.
- Animal
- Human Disease Modelled
- Intervention
- Different types or doses statins such as intensive-dose or moderate-dose atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin.
- Comparator Control
- Active control (other statin, different statin dose, other lipid-lowering medication, other non-statin lipid-lowering drugs regimens, etc), placebo or no treatment.
- Main Outcome
- The risk of new-onset diabetes Measures of effect Odds ratios (ORs) and associated 95% confidence intervals (CIs) will be estimated for the risk of new-onset diabetes in the overall population using statins.
- Outcome Measure
- Additional Outcome
- The changes in the fasting plasma glucose (FPG) or hemoglobin A1c (HbA1c) level. Measures of effect Mean difference and 95% CIs will be analyzed for the changes in the FPG or HbA1c level.
- Study Method
- Intervention, Meta-analysis, Network meta-analysis, Systematic review
- Keyword
- MeSH headings have not been applied to this record
- Contact
- Lu Chen [email protected]
- Organisational Affiliation
- Department of Pharmacy, Yantai Yuhuangding Hospital
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-10-09
- Registration Date
- 2023-10-20
- Anticipated Start Date
- 2023-08-29
- Anticipated Completion Date
- 2024-03-01
- Title Cn
- 不同类型和剂量的他汀类药物使用与新发糖尿病风险：一项网状Meta分析
- Title En
- Different Types and Doses of Statins Use and The Risk of Developing New-onset Diabetes: A Network Meta-Analysis
- Bilingual Status
- complete